GlassScriptPhysician profile
Lee B Padove
NPI 1245219500
$3,472.02
in general payments reported to CMS, 2019-2025
21 companies · $566 in 2025
The $566 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,351 · 2020: $113 · 2022: $137 · 2023: $706 · 2024: $599 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,870.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $559.47 | 2019-2025 | |
| Pfizer INC. | $515.72 | 2019-2025 | |
| Amgen INC. | $433.70 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $303.84 | 2019-2024 | Xarelto |
| Nuwellis, INC. | $284.97 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.21 | 2019-2025 | Jardiance |
| Edwards Lifesciences Corporation | $159.63 | 2019-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Astrazeneca Pharmaceuticals LP | $158.75 | 2019-2025 | Farxiga |
| Regeneron Healthcare Solutions, INC. | $120.48 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $114.77 | 2022-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.54 | 2019-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $92.85 | 2019 | |
| Merck Sharp & Dohme LLC | $84.89 | 2023 | Verquvo |
| Esperion Therapeutics, INC. | $55.73 | 2024-2025 | Nexletol |
| Kiniksa Pharmaceuticals, LTD. | $55.69 | 2022-2023 | Arcalyst |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $42.46 | 2019 | |
| Heartflow, INC. | $41.08 | 2023-2025 | Ffrct |
| Actelion Pharmaceuticals US, INC. | $22.25 | 2023 | Uptravi |
| Kiniksa Pharmaceuticals International, Plc | $18.05 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $17.09 | 2019 | |
| Kestra Medical Technology Services, INC. | $13.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Padove listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.